Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion ...
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results